Výsledky vyhledávání - "Charlotte H. Ahern"

Data from Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer Xenografts

Autor: Qizhi Yao, Changyi Chen, Craig D. Logsdon, F. Charles Brunicardi, William E. Fisher, Charlotte H. Ahern, Qihui (Jim) Zhai, Uddalak Bharadwaj, Yuqing Zhang, Min Li

Purpose: Zinc levels have been correlated with cancer risk, although the role of zinc and zinc transporters in cancer progression is largely unknown. We recently found that a zinc transporter, ZIP4, is overexpressed in pancreatic cancer. In this stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6300fcda9ea8060604883669bdcf10
https://doi.org/10.1158/1078-0432.c.6517834

Zobrazit plný text záznamu

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Autor: Mignon L. Loh, Charlotte H. Ahern, Patrick Brown, Karen R. Rabin, Susan M. Blaney, Sarah K. Tasian, Brenda J. Weigel, Daniel Magoon, Joel M. Reid, Xuejun Chen

Publikováno v: Pediatric Blood & Cancer. 62:1717-1724

Background Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. Procedure A phase 1 trial of ruxolitinib was performed to determine the maximum tolerated or recommended phase 2 dose, dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b993c9ff73b9588cb1dfa88c881a303
https://doi.org/10.1002/pbc.25575

Zobrazit plný text záznamu

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Autor: Carol A. Mercer, Helen X. Chen, Peter J. Houghton, L. Austin Doyle, Charlotte H. Ahern, Brenda J. Weigel, Darcy A. Krueger, Joel M. Reid, Susan M. Blaney, George Thomas, Maryam Fouladi, Lars M. Wagner, Alexander A. Vinks, John P. Perentesis

Publikováno v: Clinical Cancer Research. 21:1558-1565

Purpose: To determine the MTD, dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. Experimental Design: Cixutumumab and temsirol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6264fbfd1e0e14a251fc8b8378deb049
https://doi.org/10.1158/1078-0432.ccr-14-0595

Zobrazit plný text záznamu

Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma

Autor: Donald A. Barkauskas, Nino Rainusso, Daniel Fuja, Matteo Trucco, Wendy Allen-Rhoades, Laura Satterfield, Eunji Jo, Susan G. Hilsenbeck, Lawrence A. Donehower, Neha Parikh, Charlotte H. Ahern, Ryan Shuck, Jason T. Yustein, Lyazat Kurenbekova

Publikováno v: Cancer Medicine

Osteosarcoma (OS) is the primary bone tumor in children and young adults. Currently, there are no reliable, noninvasive biologic markers to detect the presence or progression of disease, assess therapy response, or provide upfront prognostic insights

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f6af7043d0c1794e01c84999f1f826e
http://europepmc.org/articles/PMC4529336

Zobrazit plný text záznamu

Plný text ve formátu HTML

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report

Autor: Timothy P. Cripe, Deborah L. Stabley, Valerie B. Sampson, Susan M. Blaney, Charlotte H. Ahern, James A. Zwiebel, E. Anders Kolb, Katia Sol-Church, Pooja Hingorani, Alexa Walter, Brenda J. Weigel

Publikováno v: Pediatric Blood & Cancer. 62:751-758

Purpose Reovirus is a naturally occurring human virus that is cytopathic to malignant cells possessing an activated Ras signaling pathway. We conducted a phase I trial of Reolysin, a manufactured, proprietary isolate of purified reovirus, in children

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76d047b0c1a816f4388e26f129356874
https://doi.org/10.1002/pbc.25464

Zobrazit plný text záznamu

A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study

Autor: Brenda J. Weigel, Matthew M. Ames, Susan M. Blaney, John P. Perentesis, Maryam Fouladi, Renee M. McGovern, Sarah Leary, Christine L Phillips, Charlotte H. Ahern, Peter J. Houghton, L. Austin Doyle, Ashish M. Ingle, Joel M. Reid

Publikováno v: Pediatric Blood & Cancer. 61:1246-1251

Background We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::429347c13eb959b7f1c4d82b80bc7ec5
https://doi.org/10.1002/pbc.25023

Zobrazit plný text záznamu

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study

Autor: Brenda J. Weigel, Rochelle Bagatell, Peter C. Adamson, Ashish M. Ingle, Stephan D. Voss, Elizabeth Fox, Susan M. Blaney, Robin E. Norris, Charlotte H. Ahern, Anthony R. Little

Publikováno v: Pediatric Blood & Cancer. 61:833-839

Background mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and temozolomide (TMZ) was conducted in children with recurrent/refractory solid tumors, including cent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::321f975a807804d52f93b52e8dffe57a
https://doi.org/10.1002/pbc.24874

Zobrazit plný text záznamu

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Autor: Brenda J. Weigel, Pamela Jo Harris, Charlotte H. Ahern, Timothy P.L. Roberts, Ashish M. Ingle, Joel M. Reid, Sylvain Baruchel, Bing Wu, Julia L. Glade Bender, Alice Lee, Stephan D. Voss, Susan M. Blaney

Publikováno v: Journal of Clinical Oncology. 31:3034-3043

Purpose Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6158aaa403f93c137f8b85d8ccefc792
https://doi.org/10.1200/jco.2012.47.0914

Zobrazit plný text záznamu

Long-term outcome of centrally located low-grade glioma in children

Autor: Eunji Jo, Ching C. Lau, Jack Su, Charlotte H. Ahern, Arnold dela Cruz Paulino, Keita Terashima, Murali Chintagumpala, Robert C. Dauser, M. Fatih Okcu, William E. Whitehead, Kevin Chow, Jeremy O. Jones, Adekunle M. Adesina, Benjamin Ellezam, Anita Mahajan

Publikováno v: Cancer. 119:2630-2638

BACKGROUND Optimal management of children with centrally located low-grade glioma (LGG) is unclear. Initial interventions in most children are chemotherapy in younger and radiation therapy (RT) in older children. A better understanding of the inheren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::572d10a65881c7acfbc0c65f69eacf76
https://doi.org/10.1002/cncr.28110

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání